Alnylam Pharmaceuticals, Inc. (BVMF:A1LN34)

Alnylam Pharmaceuticals Ratios and Metrics

Market cap in millions BRL. Fiscal year is January - December.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Feb 20, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Market Capitalization	226,557	289,363	187,715	116,555	154,568	113,005
Market Cap Growth	14.50%	54.15%	61.05%	-24.59%	36.78%	44.11%
Enterprise Value	226,867	289,631	187,381	117,806	156,293	110,728
Last Close Price	85.59	111.44	72.73	44.65	63.00	47.03
PE Ratio	131.10	167.44	-	-	-	-
PS Ratio	11.08	14.15	13.50	13.14	28.18	24.02
PB Ratio	52.12	66.57	452.40	-108.87	-184.79	34.48
P/TBV Ratio	52.12	66.57	452.40	-	-	34.48
P/FCF Ratio	88.38	112.89	-	572.67	-	-
P/OCF Ratio	78.48	100.24	-	230.62	-	-
EV/Sales Ratio	11.90	14.16	13.48	13.28	28.50	23.54
EV/EBITDA Ratio	70.00	94.37	-	-	-	-
EV/EBIT Ratio	88.15	104.84	-	-	-	-
EV/FCF Ratio	88.50	112.99	-	578.81	-	-
Debt / Equity Ratio	3.76	3.76	40.89	-12.16	-16.51	3.72
Debt / EBITDA Ratio	4.70	4.70	-	-	-	-
Debt / FCF Ratio	6.38	6.38	-	63.96	-	-
Net Debt / Equity Ratio	0.08	0.08	0.73	-1.10	-2.65	-0.42
Net Debt / EBITDA Ratio	0.11	0.11	-0.41	-1.07	-0.57	0.38
Net Debt / FCF Ratio	0.13	0.13	-1.15	5.80	-0.68	0.35
Asset Turnover	0.81	0.81	0.56	0.50	0.29	0.24
Inventory Turnover	8.46	8.46	3.86	2.85	1.57	1.74
Quick Ratio	2.51	2.51	2.61	2.86	3.17	3.79
Current Ratio	2.76	2.76	2.78	3.08	3.51	4.04
Return on Equity (ROE)	73.28%	73.28%	-	-	-526.14%	-106.31%
Return on Assets (ROA)	6.81%	6.81%	-2.74%	-4.78%	-13.65%	-12.56%
Return on Invested Capital (ROIC)	86.03%	100.88%	-255.24%	-198.35%	-261.58%	-132.10%
Return on Capital Employed (ROCE)	14.30%	14.30%	-5.80%	-9.90%	-28.30%	-24.00%
Earnings Yield	0.76%	0.60%	-0.92%	-1.83%	-3.87%	-4.21%
FCF Yield	1.13%	0.89%	-0.14%	0.18%	-2.10%	-3.54%
Buyback Yield / Dilution	-5.51%	-5.51%	-2.20%	-2.64%	-2.73%	-3.01%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.